A California team has shown that inhibiting MAGL reduces neuroinflammation in a mouse model of Parkinson's disease. The researchers are now investigating the small molecule's effects in other neurodegenerative and neurological diseases, and newco Abide Therapeutics is exercising an option to license the MAGL inhibitors.